Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Alvotech ( (ALVO) ) is now available.
On July 10, 2025, Alvotech announced the appointment of Linda Jónsdóttir as the new Chief Financial Officer, succeeding Joel Morales. Linda brings extensive experience in finance and corporate leadership, having held senior roles in various industries. Joel Morales, who has been with Alvotech since 2020, will continue in an advisory role to ensure a smooth transition. This leadership change is significant for Alvotech as it continues its growth trajectory and aims to strengthen its position as a global leader in the biosimilar industry.
The most recent analyst rating on (ALVO) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s score is primarily influenced by its financial performance, which indicates rapid growth but significant financial instability. The earnings call provided a positive outlook with raised guidance and strategic product launches. However, technical analysis shows bearish signals and valuation is moderately high, affecting the overall score.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines. The company aims to be a leader in the biosimilar space by offering high-quality, cost-effective products and services. Alvotech has a broad network of strategic commercial partnerships across various regions, including the United States, Europe, Japan, and several other markets. The company has two biosimilars already approved and marketed, with a development pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.
Average Trading Volume: 201,961
Technical Sentiment Signal: Sell
Current Market Cap: $2.66B
See more data about ALVO stock on TipRanks’ Stock Analysis page.